{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T08:45:23Z","timestamp":1771145123297,"version":"3.50.1"},"reference-count":105,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T00:00:00Z","timestamp":1595808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002261","name":"Russian Foundation for Basic Research","doi-asserted-by":"publisher","award":["19-34-60024"],"award-info":[{"award-number":["19-34-60024"]}],"id":[{"id":"10.13039\/501100002261","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Myelodysplastic syndrome (MDS) is a clonal disease characterized by multilineage dysplasia, peripheral blood cytopenias, and a high risk of transformation to acute myeloid leukemia. In theory, from clonal hematopoiesis of indeterminate potential to hematologic malignancies, there is a complex interplay between genetic and epigenetic factors, including miRNA. In practice, karyotype analysis assigns patients to different prognostic groups, and mutations are often associated with a particular disease phenotype. Among myeloproliferative disorders, secondary MDS is a group of special entities with a typical spectrum of genetic mutations and cytogenetic rearrangements resembling those in de novo MDS. This overview analyzes the present prognostic systems of MDS and the most recent efforts in the search for genetic and epigenetic markers for the diagnosis and prognosis of MDS.<\/jats:p>","DOI":"10.3390\/medicina56080376","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T10:16:49Z","timestamp":1595931409000},"page":"376","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Prognostic Markers of Myelodysplastic Syndromes"],"prefix":"10.3390","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3799-9407","authenticated-orcid":false,"given":"Yuliya Andreevna","family":"Veryaskina","sequence":"first","affiliation":[{"name":"Laboratory of Gene Engineering, Institute of Cytology and Genetics, SB RAS, 630090 Novosibirsk, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9401-5737","authenticated-orcid":false,"given":"Sergei Evgenievich","family":"Titov","sequence":"additional","affiliation":[{"name":"Department of the Structure and Function of Chromosomes, Laboratory of Molecular Genetics, Institute of Molecular and Cellular Biology, SB RAS, 630090 Novosibirsk, Russia"},{"name":"Vector-Best, 630117 Novosibirsk, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor Borisovich","family":"Kovynev","sequence":"additional","affiliation":[{"name":"Department of Therapy, Hematology and Transfusiology, Novosibirsk State Medical University, 630091 Novosibirsk, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana Ivanovna","family":"Pospelova","sequence":"additional","affiliation":[{"name":"Department of Therapy, Hematology and Transfusiology, Novosibirsk State Medical University, 630091 Novosibirsk, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor Fyodorovich","family":"Zhimulev","sequence":"additional","affiliation":[{"name":"Department of the Structure and Function of Chromosomes, Laboratory of Molecular Genetics, Institute of Molecular and Cellular Biology, SB RAS, 630090 Novosibirsk, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Mohammad, A.A. (2018). Myelodysplastic syndrome from theoretical review to clinical application view. Oncol. Rev., 12.","DOI":"10.4081\/oncol.2018.397"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/hon.2660","article-title":"The incidence, risk factors, and survival of acute myeloid leukemia secondary to myelodysplastic syndrome: A population-based study","volume":"37","author":"Ye","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_3","unstructured":"(2020, May 30). National cancer Institute SEER cancer statistics review, 1975\u20132013: Myelodysplastic Syndromes (MDS), Chronic Myeloproliferative Disorders (CMD), and Chronic Myelomonocytic Leukemia (CMML), Available online: https:\/\/seer.cancer.gov\/archive\/csr\/1975_2013\/browse_csr.php?sectionSEL=30&pageSEL=sect_30_intro.01.html."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/trf.14016","article-title":"Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphoma","volume":"57","author":"Ge","year":"2017","journal-title":"Transfusion"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Jabagi, M.J., Goncalves, A., Vey, N., Le Tri, T., Zureik, M., and Dray-Spira, R. (2019). Risk of Hematologic Malignant Neoplasms after Postoperative Treatment of Breast Cancer. Cancers, 11.","DOI":"10.3390\/cancers11101463"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1177\/147323000903700134","article-title":"Co-existent de novo myelodysplastic syndrome and T-cell non-Hodgkin lymphoma: A common origin or not?","volume":"37","author":"Huang","year":"2009","journal-title":"J. Int. Med. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1182\/blood-2018-10-844670","article-title":"MDS overlap disorders and diagnostic boundaries","volume":"133","author":"Tanaka","year":"2019","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1182\/blood-2011-03-342642","article-title":"Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers","volume":"118","author":"Naqvi","year":"2011","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1182\/blood-2013-02-451757","article-title":"The myelodysplastic syndrome as a prototypical epigenetic disease","volume":"121","author":"Issa","year":"2013","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1182\/blood-2018-10-844696","article-title":"Treatment of MDS","volume":"133","author":"Platzbecker","year":"2019","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2011.35.6394","article-title":"New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge","volume":"30","author":"Schanz","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/leu.2016.364","article-title":"Preleukemia: One name, many meanings","volume":"31","author":"Koeffler","year":"2017","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/leu.2015.55","article-title":"Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)","volume":"29","author":"Tuechler","year":"2015","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3324\/haematol.2011.044602","article-title":"Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)","volume":"96","author":"Malcovati","year":"2011","journal-title":"Haematologica"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.1002\/cncr.26173","article-title":"Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome","volume":"117","author":"Cordoba","year":"2011","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/MOH.0000000000000325","article-title":"Dyserythropoiesis of myelodysplastic syndromes","volume":"24","author":"Bondu","year":"2017","journal-title":"Curr. Opin. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.leukres.2013.12.020","article-title":"Proposal for refining the definition of dysgranulopoiesis in acute myeloid leukemia and myelodysplastic syndromes","volume":"38","author":"Goasguen","year":"2014","journal-title":"Leuk. Res."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Feng, G., Gale, R.P., Cui, W., Cai, W., Huang, G., Xu, Z., Qin, T., Zhang, Y., Li, B., and Fang, L. (2016). A systematic classification of megakaryocytic dysplasia and its impact on prognosis for patients with myelodysplastic syndromes. Exp. Hematol. Oncol., 5.","DOI":"10.1186\/s40164-016-0041-6"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1200\/EDBK_239083","article-title":"CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice","volume":"39","author":"DeZern","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1182\/blood-2017-01-763425","article-title":"Clinical significance of somatic mutation in unexplained blood cytopenia","volume":"129","author":"Malcovati","year":"2017","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrc.2016.112","article-title":"The genetics of myelodysplastic syndrome: From clonal haematopoiesis to secondary leukaemia","volume":"17","author":"Sperling","year":"2017","journal-title":"Nat. Rev. Cancer."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bcmd.2017.10.001","article-title":"Impact of chromosome alterations, genetic mutations and clonal hematopoiesis of indeterminate potential (CHIP) on the classification and risk stratification of MDS","volume":"69","author":"Ganguly","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Bennett","year":"1982","journal-title":"Br. J. Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.cancergencyto.2010.06.013","article-title":"AML Study Group of Southern Denmark: Cytogenetic findings in adult secondary acute myeloid leukemia (AML): Frequency of favorable and adverse chromosomal aberrations do not differ from adult de novo AML","volume":"202","author":"Preiss","year":"2010","journal-title":"Cancer Genet Cytogenet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/ajh.23211","article-title":"Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations","volume":"87","author":"Devillier","year":"2012","journal-title":"Am. J. Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Fernandez-Mercado, M., Yip, B.H., Pellagatti, A., Davies, C., Larrayoz, M.J., Kondo, T., P\u00e9rez, C., Killick, S., McDonald, E.J., and Odero, M.D. (2012). Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0042334"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMoa1106968","article-title":"Clonal architecture of secondary acute myeloid leukemia","volume":"366","author":"Walter","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminoncol.2005.06.021","article-title":"A comparative review of classification systems in myelodysplastic syndromes (MDS)","volume":"32","author":"Bennett","year":"2005","journal-title":"Semin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.leukres.2005.11.015","article-title":"Classification and scoring systems in myelodysplastic syndromes: A retrospective analysis of 311 patients","volume":"30","author":"Navarro","year":"2006","journal-title":"Leuk. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1182\/blood-2003-06-2124","article-title":"The WHO classification of MDS does make a difference","volume":"103","author":"Howe","year":"2004","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/ng.3742","article-title":"Dynamics of clonal evolution in myelodysplastic syndromes","volume":"49","author":"Makishima","year":"2017","journal-title":"Nat. Genet."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Nagata, Y., Makishima, H., Kerr, C.M., Przychodzen, B.P., Aly, M., Goyal, A., Awada, H., Asad, M.F., Kuzmanovic, T., and Suzuki, H. (2019). Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes. Nat. Commun., 10.","DOI":"10.1038\/s41467-019-13001-y"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.mrrev.2016.04.009","article-title":"Mutations of myelodysplastic syndromes (MDS): An update","volume":"769","author":"Ganguly","year":"2016","journal-title":"Mutat. Res. Rev. Mutat. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1038\/sj.leu.2402713","article-title":"Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001","volume":"16","author":"Mauritzson","year":"2002","journal-title":"Leukemia"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia","volume":"478","author":"Yoshida","year":"2011","journal-title":"Nature"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s10147-019-01462-6","article-title":"Genetic abnormalities and pathophysiology of MDS","volume":"24","author":"Hosono","year":"2019","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.1182\/blood-2011-09-377275","article-title":"Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic\/myeloproliferative neoplasms","volume":"118","author":"Malcovati","year":"2011","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Jafari, P.A., Sadeghian, M.H., Miri, H.H., Sadeghi, R., Bagheri, R., Lavasani, S., and Souri, S. (2020). Prognostic significance of SF3B1 mutations in patients with myelodysplastic syndromes: A meta-analysis. Crit. Rev. Oncol. Hematol., 145.","DOI":"10.1016\/j.critrevonc.2019.102832"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/leu.2014.144","article-title":"PRPF8 defects cause missplicing in myeloid malignancies","volume":"29","author":"Przychodzen","year":"2015","journal-title":"Leukemia"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1182\/blood-2011-12-399337","article-title":"Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes","volume":"119","author":"Thol","year":"2012","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/ng.1031","article-title":"Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes","volume":"44","author":"Graubert","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/j.seminoncol.2005.07.003","article-title":"Epigenetic changes in solid and hematopoietic tumors","volume":"32","author":"Toyota","year":"2005","journal-title":"Semin Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/leu.2015.211","article-title":"IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression","volume":"30","author":"DiNardo","year":"2016","journal-title":"Leukemia"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2013-09-381665","article-title":"The genetic basis of myelodysplasia and its clinical relevance","volume":"122","author":"Cazzola","year":"2013","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/16078454.2019.1657613","article-title":"Prognostic value of DNMT3A mutations in myelodysplastic syndromes: A meta-analysis","volume":"24","author":"Liang","year":"2019","journal-title":"Hematology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/ng.620","article-title":"Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes","volume":"42","author":"Nikoloski","year":"2010","journal-title":"Nat. Genet."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/leu.2010.20","article-title":"Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia","volume":"24","author":"Boultwood","year":"2010","journal-title":"Leukemia"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1182\/asheducation-2018.1.277","article-title":"Treatments targeting MDS genetics: A fool\u2019s errand? Hematology Am. Soc","volume":"30","author":"DeZern","year":"2018","journal-title":"Hematol. Educ. Program."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.3324\/haematol.2009.011528","article-title":"Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression","volume":"94","author":"Saft","year":"2009","journal-title":"Haematologica"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Bannon, S.A., and DiNardo, C.D. (2016). Hereditary Predispositions to Myelodysplastic Syndrome. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17060838"},{"key":"ref_54","first-page":"848","article-title":"Hematological Malignancies in Adults with a Family Predisposition","volume":"115","author":"Bochtler","year":"2018","journal-title":"Dtsch Arztebl Int."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1365-2141.2012.09136.x","article-title":"Marked genetic heterogeneity in familial myelodysplasia\/acute myeloid leukaemia","volume":"158","author":"Holme","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1200\/JCO.2005.05.029","article-title":"Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: Correlation with doses of epirubicin and cyclophosphamide","volume":"23","author":"Praga","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2002-11-3343","article-title":"Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: The University of Chicago series","volume":"102","author":"Smith","year":"2003","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1053\/j.seminoncol.2013.09.013","article-title":"Therapy-related myelodysplasia and acute myeloid leukemia","volume":"40","author":"Bhatia","year":"2013","journal-title":"Semin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.leukres.2014.12.006","article-title":"Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases","volume":"39","author":"Ok","year":"2015","journal-title":"Leuk. Res."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Chen, Z., Wang, S.A., Goswami, M., Tang, G., Routbort, M.J., Patel, K.P., Luthra, R., Medeiros, L.J., and Ok, C.Y. (2019). Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts. Leuk. Res., 86.","DOI":"10.1016\/j.leukres.2019.106227"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/leu.2012.347","article-title":"IDH1 and IDH2 mutations in therapy-related myelodysplastic syndrome and acute myeloid leukemia are associated with a normal karyotype and with der(1;7)(q10;p10)","volume":"27","author":"Westman","year":"2013","journal-title":"Leukemia"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Ali, S.F., Sonu, R.J., Dwyre, D.M., Jonas, B.A., and Rashidi, H.H. (2015). Translocation (6;15)(q12;q15): A Novel Mutation in a Patient with Therapy-Related Myelodysplastic Syndrome. Case Rep. Hematol., 2015.","DOI":"10.1155\/2015\/318545"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"202","DOI":"10.17546\/msd.421622","article-title":"T-cell Non-Hodgkin lymphoma associated with myelodysplasia: A case report in a child","volume":"5","author":"Reis","year":"2018","journal-title":"Med. Sci. Discov."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"508","DOI":"10.7150\/jca.30363","article-title":"Evaluation of different scoring systems and gene mutations for the prognosis of myelodysplastic syndrome (MDS) in Chinese population","volume":"11","author":"Du","year":"2020","journal-title":"J. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/leu.2017.33","article-title":"Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium","volume":"31","author":"Zeidan","year":"2017","journal-title":"Leukemia"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1038\/leu.2016.138","article-title":"Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes","volume":"30","author":"Nazha","year":"2016","journal-title":"Leukemia"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1182\/blood-2007-03-082404","article-title":"New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: Evidence from a core dataset of 2124 patients","volume":"110","author":"Haase","year":"2007","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.5858\/2008-132-1329-LOTYCA","article-title":"Loss of the Y chromosome: An age-related or clonal phenomenon in acute myelogenous leukemia\/myelodysplastic syndrome?","volume":"132","author":"Wong","year":"2008","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/(SICI)1098-2264(200001)27:1<11::AID-GCC2>3.0.CO;2-I","article-title":"Clinical significance of Y chromosome loss in hematologic disease","volume":"27","author":"Wiktor","year":"2000","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nature04632","article-title":"Human chromosome 11 DNA sequence and analysis including novel gene identification","volume":"440","author":"Taylor","year":"2006","journal-title":"Nature"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.leukres.2010.07.018","article-title":"Myelodysplastic syndromes with deletions of chromosome 11q lack cryptic MLL rearrangement and exhibit characteristic clinicopathologic features","volume":"35","author":"Wang","year":"2011","journal-title":"Leuk. Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/leu.2010.231","article-title":"Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q","volume":"25","author":"Mallo","year":"2011","journal-title":"Leukemia"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3324\/haematol.2016.152025","article-title":"Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations","volume":"102","author":"Scharenberg","year":"2017","journal-title":"Haematologica"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2011.36.1824","article-title":"Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited","volume":"30","author":"Jerez","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"6483","DOI":"10.18632\/oncotarget.14130","article-title":"Recurrent genetic defects on chromosome 5q in myeloid neoplasms","volume":"8","author":"Hosono","year":"2017","journal-title":"Oncotarget"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1038\/s41375-018-0029-9","article-title":"A decade of progress in myelodysplastic syndrome with chromosome 5q deletion","volume":"32","author":"List","year":"2018","journal-title":"Leukemia"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/leu.2011.193","article-title":"Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide","volume":"26","author":"Lange","year":"2012","journal-title":"Leukemia"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Burgos, S., Montalban-Bravo, G., and Fuente, L. (2019). Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide: A case report. Medicine, 98.","DOI":"10.1097\/MD.0000000000014011"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Jana, B., Khanfar, A., and Ninan, M. (2014). Durable hematological and major cytogenetic response in a patient with isolated 20q deletion myelodysplastic syndrome treated with lenalidomide. Case Rep. Oncol. Med., 2014.","DOI":"10.1155\/2014\/949515"},{"key":"ref_81","first-page":"42","article-title":"Therapy-related myeloid neoplasms with isolated del(20q): Comparison with cases of de novo myelodysplastic syndrome with del(20q)","volume":"206","author":"Yin","year":"2012","journal-title":"Cancer Genetics"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/bjh.12710","article-title":"Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact","volume":"164","author":"Bacher","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cncr.26279","article-title":"Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome","volume":"118","author":"Cordoba","year":"2012","journal-title":"Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0165-4608(01)00486-1","article-title":"The incidence of trisomy 8 as a sole chromosomal aberration in myeloid malignancies varies in relation to gender, age, prior iatrogenic genotoxic exposure, and morphology","volume":"130","author":"Paulsson","year":"2001","journal-title":"Cancer Genet Cytogenet."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3349\/ymj.2016.57.2.358","article-title":"Clinical Prognostic Factors in 86 Chinese Patients with Primary Myelodysplastic Syndromes and Trisomy 8: A Single Institution Experience","volume":"57","author":"Yue","year":"2016","journal-title":"Yonsei Med. J."},{"key":"ref_86","first-page":"31","article-title":"del(13q) in myeloid malignancies","volume":"6","author":"Boyer","year":"2002","journal-title":"Atlas Genet. Cytogenet. Oncol. Haematol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.3324\/haematol.2011.061127","article-title":"Favorable outcome of patients who have 13q deletion: A suggestion for revision of the WHO \u2019MDS-U\u2019 designation","volume":"97","author":"Hosokawa","year":"2012","journal-title":"Haematologica"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/leu.2009.289","article-title":"Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features","volume":"24","author":"Wang","year":"2010","journal-title":"Leukemia"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Bacher, U., Schanz, J., Braulke, F., and Haase, D. (2015). Rare cytogenetic abnormalities in myelodysplastic syndromes. Mediterr. J. Hematol. Infect. Dis., 7.","DOI":"10.4084\/mjhid.2015.034"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Couture, T., Amato, K., DiAdamo, A., and Li, P. (2018). Jumping Translocations of 1q in Myelodysplastic Syndrome and Acute Myeloid Leukemia: Report of Three Cases and Review of Literature. Case Rep. Genet., 2018.","DOI":"10.1155\/2018\/8296478"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/gcc.22760","article-title":"Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes","volume":"58","author":"Ganster","year":"2019","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cancergen.2016.04.001","article-title":"Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup","volume":"209","author":"Hong","year":"2016","journal-title":"Cancer Genet."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Shahjahani, M., Hadad, E.H., Azizidoost, S., Nezhad, K.C., and Shahrabi, S. (2019). Complex karyotype in myelodysplastic syndromes: Diagnostic procedure and prognostic susceptibility. Oncol. Rev., 13.","DOI":"10.4081\/oncol.2019.389"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1038\/s41375-018-0351-2","article-title":"TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups","volume":"33","author":"Haase","year":"2019","journal-title":"Leukemia"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1080\/10245332.2018.1510067","article-title":"Prognostic significance of monosomal karyotype in myelodysplastic syndrome: A meta-analysis","volume":"24","author":"Wu","year":"2019","journal-title":"Hematology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/leu.2010.258","article-title":"Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype","volume":"25","author":"Patnaik","year":"2011","journal-title":"Leukemia"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Hou, H., Tsai, C., Lin, C., Chou, W., Kuo, Y., Liu, C., Tseng, M., Peng, Y., Liu, M., and Liu, C. (2018). Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome. Blood Cancer J., 8.","DOI":"10.1038\/s41408-018-0074-7"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.yexcr.2014.08.033","article-title":"microRNAs in hematopoiesis","volume":"329","author":"Lazare","year":"2014","journal-title":"Exp. Cell Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/10245332.2016.1193962","article-title":"Deregulated microRNA expression and its pathogenetic implications for myelodysplastic syndromes","volume":"21","author":"Kuang","year":"2016","journal-title":"Hematology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"571","DOI":"10.4149\/neo_2017_411","article-title":"Microarray profiling defines circulating microRNAs associated with myelodysplastic syndromes","volume":"64","author":"Hrustincova","year":"2017","journal-title":"Neoplasma"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s12185-017-2201-9","article-title":"Over-expression of miR-196b-5p is significantly associated with the progression of myelodysplastic syndrome","volume":"105","author":"Wen","year":"2017","journal-title":"Int. J. Hematol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1080\/10428194.2019.1608528","article-title":"MicroRNA-661 upregulation in myelodysplastic syndromes induces apoptosis through p53 activation and associates with decreased overall survival","volume":"60","author":"Kang","year":"2019","journal-title":"Leuk. Lymphoma."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Ga\u00f1\u00e1n-G\u00f3mez, I., Wei, Y., Yang, H., Pierce, S., Bueso-Ramos, C., Calin, G., Boyano-Ad\u00e1nez, M., and Garc\u00eda-Manero, G. (2014). Overexpression of miR-125a in Myelodysplastic Syndrome CD34+ Cells Modulates NF-\u03baB Activation and Enhances Erythroid Differentiation Arrest. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0093404"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.leukres.2015.04.013","article-title":"MicroRNA-194-5p could serve as a diagnostic and prognostic biomarker in myelodysplastic syndromes","volume":"39","author":"Choi","year":"2015","journal-title":"Leuk. Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/modpathol.2014.108","article-title":"Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes","volume":"28","author":"Zuo","year":"2015","journal-title":"Mod. Pathol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/56\/8\/376\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:52:04Z","timestamp":1760176324000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/56\/8\/376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,27]]},"references-count":105,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8]]}},"alternative-id":["medicina56080376"],"URL":"https:\/\/doi.org\/10.3390\/medicina56080376","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,27]]}}}